Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“The countdown to ESMO25 Berlin starts now! Mark your calendars!
For the first time ever at ESMO25 (European Society for Medical Oncology) meeting, we’re launching a dedicated Tumour-Agnostic track
Honored to chair this amazing track, thanks to the vision of ESMO.
President Dr. Fabrice Andre and so thrilled to work with Scientific Co-Chairs Drs. Toni Choueiri and Myriam Chalabi.
Join us for 2 exceptional Special Sessions that will reshape how we approach cancer treatment beyond organ boundaries.”
More posts featuring Vivek Subbiah.